SPACE TRAVEL AND ADRC : REGENERATION FOR THE FRONTAL FRONTIER

A PIRAYESH, A MOSAHEBI, D KALASKAR
DEPARTMENT OF PLASTIC SURGERY & SURGICAL BIOTECHNOLOGY
UNIVERSITY COLLEGE LONDON

Adipose-derived regenerative cells (ADRCs), particularly adipose-derived stem cells (ADSCs), have garnered significant attention in the field of regenerative medicine, especially concerning their potential role in the treatment of osteoporosis.

Osteoporosis is characterized by a decrease in bone density and quality, leading to an increased risk of fractures. The regenerative capabilities of ADSCs, which can differentiate into various cell types, including osteoblasts, make them a promising candidate for enhancing bone regeneration and addressing the challenges posed by osteoporosis. The ease of harvesting ADSCs from adipose tissue, combined with their multipotent nature, positions them as a superior alternative to bone marrow-derived stem cells (BMSCs). Studies have shown that ADSCs can be isolated with minimal morbidity through liposuction, allowing for a more patient-friendly approach to stem cell therapy (Pop et al., 2018; Lu et al., 2014). Furthermore, these cells exhibit a robust capacity for proliferation and differentiation into osteogenic lineages, as evidenced by their ability to enhance bone regeneration in various experimental models (Arafat et al., 2017; Zimmermann et al., 2015).

For instance, Arafat et al. demonstrated that ADSCs significantly improved bone regeneration and mineralization in critical-sized mandibular defects compared to control groups, highlighting their osteogenic potential (Arafat et al., 2017). The osteogenic differentiation of ADSCs can be influenced by various factors, including the microenvironment and the presence of specific growth factors. For example, the application of bone morphogenetic proteins (BMPs), such as BMP2 and BMP7, has been shown to enhance the osteogenic differentiation of ADSCs, promoting bone formation (Hernandez-Hurtado et al., 2016; Wang et al., 2012). In a study by Wang et al., the inhibition of PTGS1 was found to promote osteogenic differentiation of ADSCs by suppressing NF-kB signaling, further illustrating the complex regulatory mechanisms that govern ADSC differentiation (Wang et al., 2019). Additionally, the paracrine effects of ADSCs, which involve the secretion of growth factors and cytokines, play a crucial role in modulating the local environment to support bone regeneration (Russo et al., 2013).

The regenerative capabilities of ADSCs extend beyond mere differentiation into osteoblasts; they also possess immunomodulatory properties that can influence the inflammatory response during bone healing. This is particularly relevant in the context of osteoporosis, where chronic inflammation can impede bone regeneration (Vériter et al., 2015; Wagner et al., 2019). The ability of ADSCs to secrete anti-inflammatory cytokines and promote angiogenesis is essential for creating a conducive environment for bone repair (Haroutunian et al., 2022). Moreover, studies have indicated that ADSCs can restore bone regeneration after conditions such as post-traumatic osteomyelitis, showcasing their versatility in various clinical scenarios (Wagner et al., 2019). Clinical applications of ADSCs in treating osteoporosis have been explored in several studies. For instance, the use of autologous ADSCs has been investigated for their potential to regenerate medullary bone-like tissue in

patients with osteonecrosis, demonstrating promising results in terms of pain reduction and functional recovery (Gotoh et al., 2018). However, while the short-term outcomes appear favorable, long-term efficacy and safety remain critical areas for further investigation, particularly concerning the risk of tumorigenesis and chromosomal instability associated with prolonged culture of stem cells (Pak, 2012; Lafosse et al., 2015). The integration of ADSCs with biomaterials, such as collagen scaffolds, has also been a focal point in enhancing their osteogenic potential. Pop et al. highlighted the effectiveness of collagen scaffolds preconditioned with ADSCs in promoting bone regeneration, emphasizing the importance of scaffold design in facilitating cell attachment and differentiation (Pop et al., 2018).

The combination of ADSCs with biocompatible materials can significantly improve the mechanical properties and biological performance of bone grafts, making them more effective in clinical applications. In summary, the potential of adipose-derived regenerative cells in the context of osteoporosis is supported by a growing body of evidence demonstrating their ability to enhance bone regeneration through multiple mechanisms, including differentiation into osteoblasts, secretion of paracrine factors, and immunomodulation. The ease of harvesting these cells, coupled with their robust regenerative capabilities, positions ADSCs as a promising therapeutic option for treating osteoporosis and related bone disorders. However, further research is necessary to elucidate the long-term safety and efficacy of ADSC therapies, as well as to optimize their application in clinical settings.

Osteoporosis, a condition characterized by weakened bones and an increased risk of fractures, poses significant health risks, particularly in the context of space travel. The microgravity environment of space exacerbates bone density loss, as astronauts experience a reduction in mechanical loading on their skeletal system, leading to accelerated bone resorption and diminished bone formation (Giri & Moll, 2022; Bhuyan et al., 2023). This phenomenon is primarily attributed to the imbalance between osteoblast activity (bone formation) and osteoclast activity (bone resorption), which is further complicated by the aging process and the inherent dysfunction of mesenchymal stem cells (MSCs) in osteoporotic conditions (Arjmand et al., 2020; Veronesi et al., 2011). Adipose-derived regenerative cells (ADRCs), particularly adipose-derived stem cells (ADSCs), present a promising therapeutic avenue to mitigate the risk of osteoporosis in astronauts prior to space travel. These cells have demonstrated the ability to differentiate into osteoblasts and promote bone regeneration, making them a potential candidate for counteracting the adverse effects of microgravity on bone health (Oommen & Alzahrani, 2015; Silva et al., 2021). Research indicates that the administration of osteogenesis-induced ADSCs can enhance bone repair and regeneration, particularly in osteoporotic models (Oommen & Alzahrani, 2015). The hypothesis that intravenous injection of these cells could lead to improved osteogenic outcomes is supported by evidence showing that ADSCs can restore bone density and function in various preclinical studies (Oommen & Alzahrani, 2015; Arjmand et al., 2020). The unique challenges posed by long-duration space missions, such as those planned for Mars exploration, necessitate innovative solutions to maintain astronaut health. The use of ADRCs could serve as a proactive measure to bolster bone health before exposure to the microgravity environment. Studies have shown that ADSCs can enhance the osteogenic potential of bone marrow stromal cells, which are often compromised in osteoporotic conditions (Veronesi et al., 2011). Furthermore, the paracrine effects of

ADSCs, which include the secretion of growth factors that promote angiogenesis and modulate inflammation, could further support bone health in the challenging conditions of space (Silva et al., 2021). Moreover, the potential for ADRCs to be administered intravenously offers a minimally invasive approach that could be easily integrated into pre-flight medical protocols. This method of administration not only simplifies the logistics of cell therapy but also ensures that the cells can circulate throughout the body, potentially enhancing their efficacy in targeting bone tissue (Oommen & Alzahrani, 2015). Given the evidence supporting the regenerative capabilities of ADSCs, their use prior to space travel could mitigate the risks associated with osteoporosis, thereby improving the overall health and performance of astronauts during long-duration missions (Giri & Moll, 2022; Bhuyan et al., 2023).

In conclusion, the integration of intravenous ADRC administration into pre-flight protocols represents a promising strategy to combat osteoporosis in astronauts.

By harnessing the regenerative potential of these cells, it may be possible to counteract the detrimental effects of microgravity on bone health, thereby ensuring the safety and well-being of crew members during extended space missions. Further research is warranted to optimize the application of ADRCs in this context and to fully understand their long-term effects on bone regeneration in the unique environment of space.